Epilepsy - Pipeline Review, H2 2016

Date: August 24, 2016
Pages: 421
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E77FD94D4DCEN
Leaflet:

Download PDF Leaflet

Epilepsy - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H2 2016’, provides an overview of the Epilepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Epilepsy
  • The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
  • The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Epilepsy
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Epilepsy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Epilepsy Overview
Therapeutics Development
Epilepsy - Therapeutics under Development by Companies
Epilepsy - Therapeutics under Investigation by Universities/Institutes
Epilepsy - Pipeline Products Glance
Epilepsy - Products under Development by Companies
Epilepsy - Products under Investigation by Universities/Institutes
Epilepsy - Companies Involved in Therapeutics Development
Epilepsy - Therapeutics Assessment
Drug Profiles
Epilepsy - Dormant Projects
Epilepsy - Discontinued Products
Epilepsy - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Epilepsy, H2 2016
Number of Products under Development for Epilepsy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Investigation by Universities/Institutes, H2 2016
Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
Epilepsy - Pipeline by Advicenne, H2 2016
Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016
Epilepsy - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
Epilepsy - Pipeline by Aestus Therapeutics, Inc., H2 2016
Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016
Epilepsy - Pipeline by Anavex Life Sciences Corp., H2 2016
Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016
Epilepsy - Pipeline by Astellas Pharma Inc., H2 2016
Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H2 2016
Epilepsy - Pipeline by BioCrea GmbH, H2 2016
Epilepsy - Pipeline by Biogen Inc, H2 2016
Epilepsy - Pipeline by Bionomics Limited, H2 2016
Epilepsy - Pipeline by Biovista Inc., H2 2016
Epilepsy - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016
Epilepsy - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
Epilepsy - Pipeline by D-Pharm Ltd., H2 2016
Epilepsy - Pipeline by Eisai Co., Ltd., H2 2016
Epilepsy - Pipeline by Glialogix, Inc., H2 2016
Epilepsy - Pipeline by Grifols, S.A., H2 2016
Epilepsy - Pipeline by GW Pharmaceuticals Plc, H2 2016
Epilepsy - Pipeline by H. Lundbeck A/S, H2 2016
Epilepsy - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Epilepsy - Pipeline by INSYS Therapeutics, Inc., H2 2016
Epilepsy - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
Epilepsy - Pipeline by Iproteos S.L., H2 2016
Epilepsy - Pipeline by Johnson & Johnson, H2 2016
Epilepsy - Pipeline by Knopp Biosciences LLC, H2 2016
Epilepsy - Pipeline by Lead Discovery Center GmbH, H2 2016
Epilepsy - Pipeline by Lipicard Technologies Limited, H2 2016
Epilepsy - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016
Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016
Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
Epilepsy - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
Epilepsy - Pipeline by Neurelis, Inc., H2 2016
Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H2 2016
Epilepsy - Pipeline by Neuron Biopharma SA, H2 2016
Epilepsy - Pipeline by Novartis AG, H2 2016
Epilepsy - Pipeline by OPKO Health, Inc., H2 2016
Epilepsy - Pipeline by Ovid Therapeutics Inc., H2 2016
Epilepsy - Pipeline by Pfizer Inc., H2 2016
Epilepsy - Pipeline by PharmatrophiX, Inc., H2 2016
Epilepsy - Pipeline by Promius Pharma, LLC, H2 2016
Epilepsy - Pipeline by PTC Therapeutics, Inc., H2 2016
Epilepsy - Pipeline by Retrophin Inc., H2 2016
Epilepsy - Pipeline by Sage Therapeutics, Inc., H2 2016
Epilepsy - Pipeline by Saniona AB, H2 2016
Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H2 2016
Epilepsy - Pipeline by Shire Plc, H2 2016
Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Epilepsy - Pipeline by Suda Ltd, H2 2016
Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Epilepsy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Epilepsy - Pipeline by Trillium Therapeutics Inc., H2 2016
Epilepsy - Pipeline by Turing Pharmaceuticals AG , H2 2016
Epilepsy - Pipeline by UCB S.A., H2 2016
Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016
Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016
Epilepsy - Pipeline by Vichem Chemie Research Ltd., H2 2016
Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H2 2016
Epilepsy - Pipeline by Vitality Biopharma Inc, H2 2016
Epilepsy - Pipeline by Xenon Pharmaceuticals Inc., H2 2016
Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016
Epilepsy - Pipeline by Zogenix, Inc., H2 2016
Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Epilepsy - Dormant Projects, H2 2016
Epilepsy - Dormant Projects (Contd..1), H2 2016
Epilepsy - Dormant Projects (Contd..2), H2 2016
Epilepsy - Dormant Projects (Contd..3), H2 2016
Epilepsy - Dormant Projects (Contd..4), H2 2016
Epilepsy - Dormant Projects (Contd..5), H2 2016
Epilepsy - Dormant Projects (Contd..6), H2 2016
Epilepsy - Dormant Projects (Contd..7), H2 2016
Epilepsy - Dormant Projects (Contd..8), H2 2016
Epilepsy - Dormant Projects (Contd..9), H2 2016
Epilepsy - Discontinued Products, H2 2016
Epilepsy - Discontinued Products (Contd..1), H2 2016

LIST OF FIGURES

Number of Products under Development for Epilepsy, H2 2016
Number of Products under Development for Epilepsy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Bionomics Limited - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 45 pages

Ask Your Question

Epilepsy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: